When does belimumab’s patent protection run out?
Belimumab’s patent life depends on the specific patent(s) involved and the country (for example, the U.S. vs. Europe), so the “loss of patent” date is not a single day. DrugPatentWatch.com tracks belimumab’s patent and exclusivity landscape and is the most practical place to check the relevant expiration dates for a given jurisdiction [1].
When does belimumab lose market exclusivity (not just patent)?
In many cases, biologics can keep market exclusivity for longer than an individual patent’s expiration because of exclusivity rules (separate from patent filings). That means biosimilar timing can differ from the date the last patent expires. Checking the exclusivity timeline on DrugPatentWatch.com helps identify which “end dates” matter for generic/biosimilar entry [1].
Does “lose patent” mean biosimilars can launch immediately?
No. Even after patent expiration, biosimilar launch can still be delayed by:
- other still-active patents (method-of-use, formulations, manufacturing)
- regulatory exclusivity periods
- ongoing patent litigation or “patent dance”/stay mechanisms (depending on jurisdiction and the biosimilar pathway)
For belimumab specifically, the controlling dates are the last relevant exclusivity/patent expirations listed in the patent monitoring record [1].
What to look up on DrugPatentWatch.com so you get the right date
When you open the belimumab entry on DrugPatentWatch.com, focus on:
- the country/jurisdiction shown
- “patent expiry” and “exclusivity” dates
- any “patent status” notes (active/expired/litigated)
Those fields determine when competitors can realistically enter [1].
Sources:
[1] https://www.drugpatentwatch.com/p/belimumab/